Baxis Pharmaceuticals, Inc.
Quick facts
Phase 3 pipeline
- Fusidic Acid 1% · Infectious Disease
Fusidic acid inhibits bacterial protein synthesis by binding to elongation factor G and preventing peptide chain elongation.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Baxis Pharmaceuticals, Inc.
What is Baxis Pharmaceuticals, Inc.'s pipeline?
Baxis Pharmaceuticals, Inc. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Fusidic Acid 1%.
Related
- Sector hub: All tracked pharma companies